Research output per year
Research output per year
Fingerprint
Dive into the research topics where Eric J Lawitz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B-Assured)
Noormohamed, N., Lukic, T., Marbury, T. C., Lawitz, E. J., Prescott, H., Magee, M., Nader, A. & Han, K., Oct 2024, In: Clinical Pharmacology in Drug Development. 13, 10, p. 1088-1097 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
for the 1404-0043 Trial Investigators, Jul 25 2024, In: New England Journal of Medicine. 391, 4, p. 311-319 9 p.Research output: Contribution to journal › Article › peer-review
Open Access57 Scopus citations -
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W. S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L. & Harrison, S. A., Mar 2024, In: Hepatology. 79, 3, p. 674-689 16 p.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations -
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Ratziu, V., Hompesch, M., Petitjean, M., Serdjebi, C., Iyer, J. S., Parwani, A. V., Tai, D., Bugianesi, E., Cusi, K., Friedman, S. L., Lawitz, E., Romero-Gómez, M., Schuppan, D., Loomba, R., Paradis, V., Behling, C. & Sanyal, A. J., Feb 2024, In: Journal of Hepatology. 80, 2, p. 335-351 17 p.Research output: Contribution to journal › Review article › peer-review
Open Access20 Scopus citations -
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
Loomba, R., Bedossa, P., Grimmer, K., Kemble, G., Bruno Martins, E., McCulloch, W., O'Farrell, M., Tsai, W. W., Cobiella, J., Lawitz, E., Rudraraju, M. & Harrison, S. A., Dec 2024, In: The Lancet Gastroenterology and Hepatology. 9, 12, p. 1090-1100 11 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations
Datasets
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764.v1, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764/1
Dataset
-
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Zoulim, F. (Creator), Moreno, C. (Creator), Lee, S. S. (Creator), Buggisch, P. (Creator), Horban, A. (Creator), Lawitz, E. (Creator), Corbett, C. (Creator), Lenz, O. (Creator), Fevery, B. (Creator), Verbinnen, T. (Creator), Shukla, U. (Creator) & Jessner, W. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.3990051, https://figshare.com/collections/A_3-year_follow-up_study_after_treatment_with_simeprevir_in_combination_with_pegylated_interferon-_and_ribavirin_for_chronic_hepatitis_C_virus_infection/3990051
Dataset
-
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Zoulim, F. (Creator), Moreno, C. (Creator), Lee, S. S. (Creator), Buggisch, P. (Creator), Horban, A. (Creator), Lawitz, E. (Creator), Corbett, C. (Creator), Lenz, O. (Creator), Fevery, B. (Creator), Verbinnen, T. (Creator), Shukla, U. (Creator) & Jessner, W. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.3990051.v1, https://springernature.figshare.com/collections/A_3-year_follow-up_study_after_treatment_with_simeprevir_in_combination_with_pegylated_interferon-_and_ribavirin_for_chronic_hepatitis_C_virus_infection/3990051/1
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764
Dataset